Zydus Therapeutics
CompanyUnited States
Zydus Therapeutics develops one asset, in phase 3 (Saroglitazar magnesium in primary biliary cholangitis). Mostly small molecule acting on lipid and ceramide metabolism, PPARG and PPARA; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Activates PPAR alpha and gamma to regulate lipid metabolism and improve insulin sensitivity.
Phase 3, Small molecule, Lipid and ceramide metabolism, PPARG, primary biliary cholangitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals1
- Similar companies6